Bio-Thera Solutions Ltd (688177) - Net Assets
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) has net assets worth CN¥583.12 Million CNY (≈ $85.33 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.25 Billion ≈ $328.76 Million USD) and total liabilities (CN¥1.66 Billion ≈ $243.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bio-Thera Solutions Ltd (688177) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥583.12 Million |
| % of Total Assets | 25.95% |
| Annual Growth Rate | 3.58% |
| 5-Year Change | -64.69% |
| 10-Year Change | N/A |
| Growth Volatility | 89.28 |
Bio-Thera Solutions Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 688177 asset base for the complete picture of this company's asset base.
Annual Net Assets for Bio-Thera Solutions Ltd (2016–2024)
The table below shows the annual net assets of Bio-Thera Solutions Ltd from 2016 to 2024. For live valuation and market cap data, see Bio-Thera Solutions Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥708.09 Million ≈ $103.62 Million |
-41.61% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.46 Million |
-24.55% |
| 2022-12-31 | CN¥1.61 Billion ≈ $235.19 Million |
-23.01% |
| 2021-12-31 | CN¥2.09 Billion ≈ $305.47 Million |
+4.08% |
| 2020-12-31 | CN¥2.01 Billion ≈ $293.48 Million |
+218.01% |
| 2019-12-31 | CN¥630.67 Million ≈ $92.29 Million |
-21.30% |
| 2018-12-31 | CN¥801.32 Million ≈ $117.26 Million |
+130.56% |
| 2017-12-31 | CN¥347.55 Million ≈ $50.86 Million |
-34.97% |
| 2016-12-31 | CN¥534.43 Million ≈ $78.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-Thera Solutions Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 250195447232.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥3.47 Billion | 490.64% |
| Total Equity | CN¥708.09 Million | 100.00% |
Bio-Thera Solutions Ltd Competitors by Market Cap
The table below lists competitors of Bio-Thera Solutions Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Power HF Co Ltd
SHG:605100
|
$1.23 Billion |
|
Heidrick & Struggles International
NASDAQ:HSII
|
$1.23 Billion |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
$1.23 Billion |
|
Astec Industries Inc
NASDAQ:ASTE
|
$1.23 Billion |
|
Azorim Investment Development and Construction Co Ltd
TA:AZRM
|
$1.23 Billion |
|
Tanac Automation Co Ltd
SHE:300461
|
$1.22 Billion |
|
Zhe Jiang Headman Machinery Co Ltd
SHG:688577
|
$1.22 Billion |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
$1.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-Thera Solutions Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,212,715,421 to 708,089,002, a change of -504,626,418 (-41.6%).
- Net loss of 510,303,807 reduced equity.
- Dividend payments of 20,600,182 reduced retained earnings.
- Other factors increased equity by 26,277,571.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-510.30 Million | -72.07% |
| Dividends Paid | CN¥20.60 Million | -2.91% |
| Other Changes | CN¥26.28 Million | +3.71% |
| Total Change | CN¥- | -41.61% |
Book Value vs Market Value Analysis
This analysis compares Bio-Thera Solutions Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.61x to 11.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.98 | CN¥20.23 | x |
| 2018-12-31 | CN¥2.26 | CN¥20.23 | x |
| 2019-12-31 | CN¥1.78 | CN¥20.23 | x |
| 2020-12-31 | CN¥4.84 | CN¥20.23 | x |
| 2021-12-31 | CN¥5.04 | CN¥20.23 | x |
| 2022-12-31 | CN¥3.88 | CN¥20.23 | x |
| 2023-12-31 | CN¥2.93 | CN¥20.23 | x |
| 2024-12-31 | CN¥1.71 | CN¥20.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-Thera Solutions Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.67%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 3.11x
- Recent ROE (-72.07%) is below the historical average (-53.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -25.56% | -4942.14% | 0.00x | 1.33x | CN¥-190.03 Million |
| 2017 | -67.76% | -11723.31% | 0.00x | 1.78x | CN¥-270.26 Million |
| 2018 | -69.02% | 0.00% | 0.00x | 1.27x | CN¥-633.24 Million |
| 2019 | -162.15% | -146088.83% | 0.00x | 1.61x | CN¥-1.09 Billion |
| 2020 | -25.59% | -277.43% | 0.08x | 1.19x | CN¥-713.79 Million |
| 2021 | 3.93% | 9.79% | 0.32x | 1.25x | CN¥-126.81 Million |
| 2022 | -29.89% | -105.55% | 0.21x | 1.36x | CN¥-641.12 Million |
| 2023 | -32.53% | -55.98% | 0.31x | 1.89x | CN¥-515.80 Million |
| 2024 | -72.07% | -68.67% | 0.34x | 3.11x | CN¥-581.11 Million |
Industry Comparison
This section compares Bio-Thera Solutions Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,387,359,426
- Average return on equity (ROE) among peers: 2.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-Thera Solutions Ltd (688177) | CN¥583.12 Million | -25.56% | 2.85x | $1.23 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $948.24 Million | -53.63% | 0.17x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $304.67 Million | -9.25% | 1.53x | $444.78 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.06 Billion | 8.06% | 0.08x | $444.44 Million |
| Chengzhi Shareholding Co Ltd (000990) | $15.52 Billion | 0.71% | 0.30x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.87 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.25 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $5.41 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $568.58 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.91 Billion |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more